HilleVax (HLVX) Q4 2024 earnings summary

Executive summary

• Ended 2024 with $171.4 million in cash, cash equivalents, and marketable securities, down from $303.5 million at the end of 2023.

• Focused on developing norovirus vaccine candidates HIL-214 and HIL-216, with ongoing exploration of strategic alternatives and business development activities.

Financial highlights

• Research and development expenses decreased to $78.2 million for 2024 from $106.7 million in 2023, mainly due to lower clinical development costs.

• General and administrative expenses rose to $28.8 million in 2024 from $26.7 million in 2023, primarily due to higher personnel costs.

• Net loss for 2024 was $147.3 million, compared to $123.6 million in 2023.

• Other income for 2024 was $8.0 million, down from $9.8 million in 2023, mainly due to interest expense on term loan repayment.

• Restructuring and impairment charges totaled $20.8 million in 2024.

Outlook and guidance

• Exploring continued development of norovirus vaccine candidates in adults and considering strategic alternatives, including business development activities.